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Abstract 
Background: The assessment of fibrosis and inflammatory activity is essential to identify patients with non-alcoholic 
fatty liver disease (NAFLD) at risk for progressive disease. Serum markers and ultrasound-based methods can replace 
liver biopsy for fibrosis staging, whereas non-invasive characterization of inflammatory activity remains a clinical 
challenge. Cell-free DNA (cfDNA) is a novel non-invasive biomarker for assessing cellular inflammation and cell death, 
which has not been evaluated in NAFLD.
Methods: Patients and healthy controls from two previous studies were included. NAFLD disease activity and sever-
ity were non-invasively characterized by liver stiffness measurement (transient elastography, TE) including steatosis 
assessment with controlled attenuation parameter (CAP), single-proton magnetic resonance spectroscopy (1H-MRS) 
for determination of hepatic fat fraction, aminotransferases and serum ferritin. cfDNA levels (90 and 222 bp fragments) 
were analyzed using quantitative real-time PCR.
Results: Fifty-eight NAFLD patients (age 62 ± 11 years, BMI 28.2 ± 3.5 kg/m2) and 13 healthy controls (age 
38 ± 12 years, BMI 22.4 ± 2.1 kg/m2) were included. 90 bp cfDNA levels were significantly higher in NAFLD patients 
compared to healthy controls: 3.7 (1.3–23.1) vs. 2.9 (1.4–4.1) ng/mL (p = 0.014). In the NAFLD cohort, circulat-
ing cfDNA correlated significantly with disease activity and severity, especially in patients with elevated liver stiff-
ness (n = 13, 22%) compared to cases with TE values ≤7 kPa: cf90 bp 6.05 (2.41–23.13) vs. 3.16 (1.29–7.31) ng/mL 
(p < 0.001), and cf222 bp 14.41 (9.27–22.90) vs. 11.32 (6.05–18.28) ng/mL (p = 0.0041).
Conclusions: Cell-free DNA plasma concentration correlates with established non-invasive markers of NAFLD activity 
and severity. Therefore, cfDNA should be further evaluated as biomarker for identifying patients at risk for progressive 
NAFLD.
Keywords: Controlled attenuation parameter, Transient elastography, Cell-free DNA, MR-spectroscopy, Non-alcoholic 
fatty liver disease, Non-alcoholic steatohepatitis
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Background
Non-alcoholic fatty liver disease (NAFLD) is an emerging 
worldwide epidemic, which will replace viral hepatitis as 
major cause of hepatic mortality within the next decades 
[1]. The spectrum of NAFLD comprises both simple stea-
tosis and non-alcoholic steatohepatitis (NASH): while 
simple steatosis has a low risk of disease progression, a 
relevant proportion of NASH patients will develop fibro-
sis and ultimately cirrhosis [2]. In this regard, presence of 
fibrosis is the strongest predictor for liver related mor-
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Traditionally, liver biopsy is considered as the gold 
standard method for the diagnosis and fibrosis stag-
ing of NAFLD [4]. However, due to potential complica-
tions and diagnostic limitations (i.e. sampling errors and 
restricted repeatability), various non-invasive techniques 
for diagnosis and estimation of disease severity have been 
proposed [5]. Among them, ultrasound-based meth-
ods for assessment of liver stiffness (elastography) have 
shown high accuracy in discriminating patients at risk 
for advanced fibrosis and impaired prognosis in differ-
ent chronic liver diseases including NAFLD [6]. Recent 
advancements of elastography methods allow the char-
acterization of liver steatosis simultaneously with liver 
stiffness measurement (LSM), e.g. with the controlled 
attenuation parameter (CAP) software [7]. However, 
while non-invasive estimation of fibrosis and liver stea-
tosis has already been implemented in clinical practice, 
serum-based biomarkers for the presence of NASH such 
as liver enzymes and ferritin show limited accuracy, 
although they are widely used in clinical practice [4, 5]. 
Hence, the precise characterization of hepatic inflamma-
tory activity still relies on histological assessment, which 
is a major drawback for diagnosis of NASH in clinical 
practice [1].
Facing the increasing prevalence of NAFLD, there is 
an urgent need to identify patients with NASH at risk 
for progressive disease with non-invasive markers that 
can be used as a point-of care approach [5]. In this line, 
several laboratory and ultrasound based markers have 
been approved for estimation of fibrosis severity, whereas 
non-invasive characterization of hepatic inflammation 
remains a diagnostic challenge [1, 6]. Cell-free plasma 
DNA (cfDNA) consists of small nucleic acid fragments 
originating from destructed cells that circulate in the 
blood stream. cfDNA levels correlate with disease stage 
and severity of tissue damage in several clinical condi-
tions [8], especially in patients with malignant diseases 
where it may represent a sensitive approach for diagnosis 
of occult tumors and metastases [9, 10]. Studies on oxida-
tive stress and inflammatory response suggest a potential 
diagnostic value of cfDNA in liver disease as well [11]. 
Particularly due to its short half-life of minutes to hours 
cfDNA might provide a snapshot of current disease activ-
ity [9]. However, the diagnostic value of cfDNA has not 
yet been studied in NAFLD patients. We therefore ana-




For the present analysis, blood samples from two pre-
vious published cohorts have been analyzed (Fig.  1). 
From the initial cohorts, only patients with reliable liver 
stiffness measurement (LSM) [12], single-proton mag-
netic resonance spectroscopy (1H-MRS) [13] and ele-
vated hepatic fat content defined by CAP ≥ 248 dB/m [7] 
were included in final analysis.
Ultrasound‑bases liver stiffness and steatosis assessment
Liver stiffness was measured using transient elastography 
(TE) according to the manufacturer’s recommendation as 
described before [14, 15]: In brief, all participants under-
went conventional ultrasound to rule out mechanical 
cholestasis or congestive liver disease. Skin-to-liver-cap-
sule distance at the TE measuring site was recorded with 
a high frequency linear transducer. For the present analy-
sis, only subjects eligible for TE M-probe with an skin-to-
liver-capsule distance ≤25 mm were included. Cases with 
fewer than 10 valid measurements or an interquartile 
range (IQR) >30% of the median LSM value (only in cases 
with liver stiffness ≥7.1 kPa) were excluded. According to 
Wong et  al. [16], LSM values  >7.0  kPa indicated risk of 
fibrosis and LSM values  >9.6  kPa defined a high risk of 
advanced fibrosis.
Controlled attenuation parameter is a measure of TE 
ultrasonic signal attenuation and was computed simul-
taneously during LSM using the M-probe [14, 15]. CAP 
values ≥248 dB/m defined presence of hepatic steatosis. 
CAP values >282 dB/m indicated advanced steatosis [7].
Magnetic resonance spectroscopy and volumetry
Patients underwent MRI examination at 1.5 T according 
to a previously described protocol [14, 15]. Single-voxel 
proton magnetic resonance spectroscopy (1H-MRS) was 
used to assess the hepatic lipid components. In short, 
voxels (20 × 20 × 20 mm3) were placed in the right liver 
lobe avoiding bile ducts and larger vessels. Relative lipid 
Fig. 1 Definition of the patient cohort. NAFLD non-alcoholic fatty 
liver disease, CAP controlled attenuation parameter, TE transient 
elastography, MR magnetic resonance
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concentrations were measured with a commercial MRS 
analysis tool (LCModel, Oakville, Canada). Spectroscopic 
peak areas of water and fat were corrected for T2 relaxa-
tion effects and used to calculate the hepatic fat fraction 
(in %) [14, 15].
Laboratory assessment
Routine liver function tests were available from the 
original study databases. None of the patients had ala-
nine aminotransferase (ALT) or aspartate aminotrans-
ferase (AST) levels >5× upper limit of normal (ULN), as 
defined by the initial study protocols [14, 15].
In addition, stored ethylenediaminetetraacetic acid 
(EDTA) blood samples (centrifuged at 1000g for 10 min 
within 2  h after collection; plasma layer carefully trans-
ferred to a new vial and stored at −20 °C) were available 
and used for deoxyribonucleic acid (DNA) extraction.
DNA extraction
After equilibrating probes to room temperature, plasma 
was centrifuged at 1000g for 10 min to remove any pos-
sible remaining cell components.
Cell-free DNA was extracted from 200  µL plasma 
using the QIAamp Blood DNA Mini kit (Qiagen) accord-
ing to the manufacture’s instructions (spin protocol). To 
increase the yield of DNA the time of incubation with AE 
buffer was prolonged from 5  min to 10  min. The DNA 
was eluted in 50 µL AE buffer and stored at −20  °C for 
at least 24  h before polymerase chain reaction (PCR) 
analysis.
PCR analysis
Cell-free plasma DNA was quantified by real time PCR 
(qPCR) using the 7500 Real Time PCR System (Applied 
Biosystems by Life Technologies,). Two sets of primers 
were used amplifying a 90 and a 222 bp fragment (cf90, 
cf222), respectively. Both fragments were amplified using 
the same forward primer (5′-TGCCGCAATAAACAT 
ACGTG-3′) and a different reverse primer (cf90: 
5′-GACCCAGCCATCCCATTAC-3′, cf222: 5′-AACAAC 
AGGTGCTGGAGAGG-3′). Both fragments are found 
on the L1PA2 element which is a LINE sequence. LINEs 
(long-interspearsed nulear elements) are non-coding 
DNA which show thousands of repeats in the human 
genome. Primers for both LINE1 fragments were taken 
from the literature [17]. Reactions were set up in a total 
volume of 20  µL including 10  µL  GoTaq® Mastermix 
(Promega), 8  µL nuclease free water, 0.5  µL forward 
primer (10 µM), 0.5 µL reverse primer (10 µM) and 1 µL 
of extracted DNA eluted in AE buffer. Cycling conditions 
were set up as recommended by the producer: initial acti-
vation for 2 min at 95 °C and 40 cycles of denaturation at 
95 °C for 15 s and annealing and extension first at 55 °C 
for 30 s, subsequently heated up to 60 °C for 1 min. Final 
extension followed at 72 °C for 5 min and then the plate 
was cooled down to 4  °C. Non-template controls were 
included on each PCR plate to confirm the absence of 
contamination. The efficiency and specificity of the prim-
ers was previously described [17, 18]. The qPCR results 
were analyzed using the 7500 Software (v2.0.6).
To quantify the cfDNA a standard curve was gener-
ated. Therefore, blood was taken from a healthy volun-
teer and the yield of total DNA extracted from 200  µL 
whole blood with QIAmp Blood DNA Mini kit as 
described above. A PCR was performed from the eluate 
with the  GoTaq® qPCR Master Mix (Promega) to obtain 
the respective fragment and concentration was meas-
ured using the Nanodrop 2000 (Thermo Fisher Scien-
tific Inc.). The PCR-product was cleaned up from spare 
nucleotides and primers by Rapid PCR clean up enzyme 
set (New England BioLabs GmbH), then concentration 
was measured with the Nanodrop 2000 and a dilution 
series was made (1; 1:10; 1:100; 1:500; 1:1000; 1:2000; 
1:4000; 1:8000; 1:16,000; 1:32,000; 1:64,000; 1:128,000; 
1:256,000; 1:512,000). For each dilution a threshold cycle 
was determined and at least three dilutions of the follow-
ing (1:16,000; 1:32,000; 1:64,000; 1:128,000; 1:256,000; 
1:512,000) were measured in every reaction plate. The 
threshold cycles for each dilution were used to generate 
a standard curve for the determination of cfDNA yield in 
every probe.
DNA integrity index analysis
The DNA integrity index is a measure of the ratio of 
short and long cfDNA fragments and provides informa-
tion on the origin of cfDNA, since smaller fragments are 
primarily released in apoptosis, while the release of larger 
fragments has mainly been described in mechanisms of 
uncontrolled cell death [19, 20]. DNA used for the stand-
ard curve was used as reference to determine the relative 
DNA strand integrity in plasma DNA. ∆Ct222 was calcu-
lated subtracting the Ct value for the 222 bp fragment of 
a sample from the reference. Also, the ∆Ct90 was calcu-
lated with the Ct value for the 90 bp fragment of a sam-
ple. To obtain a ∆∆Ct value the ∆Ct value for 222 bp was 
subtracted from the ∆Ct value for the 90 bp. The integ-
rity index was calculated for each probe as exponential of 
(−∆∆Ct × LN 2) as described before [19, 20].
Statistical analysis
Statistical analyses were performed using commercial 
software Prism 6 (GraphPad Software, La Jolla, CA, 
USA) and R version 3.3 with the lme4 package [21]. Cat-
egorical variables are expressed as frequencies and per-
centages; continuous variables were expressed either 
as mean ±  standard deviation or median and range, as 
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appropriate. Non-parametric tests (Mann–Whitney U 
test, Kruskal–Wallis test with post hoc analysis using 
the Dunn procedure) were used for comparison of inde-
pendent samples. For mean values, the t test was applied. 
Multivariate analyses were performed using linear mixed 
models where PCR batch was taken as a random effect. 
Model selection was based on Akaike’s Information Cri-
terion (AIC). Pearson correlation coefficients were cal-
culated to analyze the degree of association between two 
variables. For determination of optimal diagnostic cut-
offs, receiver operating characteristics (ROC) analysis by 
maximizing the Youden index were performed. Statistical 
significance was defined as p < 0.05.
Results
Clinical characteristics of the study cohorts
58 NAFLD patients and 13 healthy controls matched 
the inclusion criteria and were eligible for the analysis 
(Fig.  1). Clinical characteristics of the study cohort are 
assorted in Table 1.
NAFLD patients were characterized by higher age, 
higher BMI, and higher WHR values compared to the 
healthy controls (p < 0.0001, respectively) and showed a 
high prevalence of features of the metabolic syndrome: 
overweight (BMI > 25 kg/m2) 79%; obesity (BMI > 30 kg/
m2) 28%; type 2 diabetes 64%).
Serum ALT and AST levels were significantly higher 
in NAFLD patients than in healthy controls (p < 0.0001, 
respectively). In the NAFLD cohort, elevated ALT 
and AST were observed in 26 and 18 cases (45 and 
31%, respectively). In 12 cases (21%) both values were 
increased concurrently. Seventeen patients (30%) had 
elevated serum ferritin levels.
Because of the substantial differences between the 
cohorts, the primary analyses were performed in the 
NAFLD cohort alone.
Liver stiffness and liver steatosis measurement
All healthy controls had normal LSM values as defined 
by the protocol (Table  1). Among NAFLD patients, 13 
(22%) had increased LSM values over 7.0 kPa indicative 
of inflammation and fibrosis. In these patients, 10 (17%) 
had LSM values higher than 9.6 kPa indicating high risk 
of advanced fibrosis.
Controlled attenuation parameter classified NAFLD 
patients as follows [7]: mild steatosis (CAP ≤ 268 dB/m) 
n  =  7 (12%), moderate steatosis (CAP 269–282  dB/m) 
n = 9 (16%), and advanced steatosis (CAP > 282 dB/m) 
n = 42 cases (72%), respectively.
MR spectroscopy showed a significant difference 
in hepatic fat between healthy controls and NAFLD 
patients. Of these, 33 patients (57%) had relative hepatic 
lipid content values over 10%.
In NAFLD patients, 1H-MRS and CAP values were 
correlated (r  =  0.466), whereas liver stiffness did not 
correlate with either CAP (r  =  0.036), or 1H-MRS 
(r = 0.063).
Association of cfDNA with anthropometry and factors 
of the metabolic syndrome
The cf90 fragment concentrations were increased in the 
NAFLD cohort compared to the healthy controls: 3.7 
(1.3–23.1) vs. 2.9 (1.4–4.1) ng/mL, (p  =  0.014). There 
was a similar tendency for cf222: 11.54 (6.1–22.9) vs. 10.8 
(6.4–15.0) ng/mL (p = 0.054).
In the NAFLD cohort, no significant association of 
cfDNA (both fragments) with age, BMI or presence of 
type 2 diabetes was detected in a linear mixed model, 
but there was a dependence on sex in the case of cf222 
(2.4 ng/mL lower for men, p = 0.0051). The model with-
out age, BMI and type 2 diabetes had a lower AIC, so that 
we retained only sex for further analyses. To have a con-
sistent model, sex was also used for cf90.
Association of cfDNA with NAFLD severity
NAFLD patients with increased liver stiffness (>7.0 kPa) 
had significantly higher cf90 and cf222 fragment 
Table 1 Baseline characteristics of the study cohort
BMI body mass index, HbA1c hemoglobin A1c, ALT alanine aminotransferase, AST 
aspartate aminotransferase, ULN upper limit of normal, 1H-MRS single-proton 
magnetic resonance spectroscopy, CAP controlled attenuation parameter, rHLC 
relative hepatic lipid content
a  Values presented as mean and standard deviation
b  Values presented as median and range
Controls n = 13 NAFLD cohort n = 58
Anthropometry
 Sex (male/female) 6 (46.2%)/7 (53.8%) 32 (55.2%)/26 (44.8%)
 Age  (yearsa) 37.7 ± 11.5 62.1 ± 11.0
 BMI (kg/m2a) 22.4 ± 2.1 28.2 ± 3.5
  <25 (n) 11 (84.6%) 12 (20.7%)
  25–30 (n) 2 (15.4%) 30 (51.7%)
  30–35 (n) 0 (0%) 15 (25.9%)
  >35 (n) 0 (0%) 1 (1.7%)
 Waist-to-hip  (ratioa) 0.87 ± 0.14 0.96 ± 0.09
 Diabetes (n) 0 (0%) 37 (63.8%)
Laboratory values
 HbA1c (%b) 5.0 (4.7–5.4) 5.7 (4.6–8.0)
 ALT/ULN  (ratiob) 0.4 (0.3–0.6) 0.9 (0.3–3.3)
 AST/ULN  (ratiob) 0.5 (0.4–0.7) 0.8 (0.3–2.1)
 Ferritin/ULN  (ratiob) 0.3 (0.05–2.0) 0.7 (0.1–5.5)
Non-invasive liver assessment
 1H-MRS  (rHLCb) 0.8 (0–8.6) 12.8 (1.2–41.1)
 CAP (dB/mb) 210 (100–231) 310 (249–397)
 Liver stiffness  (kPab) 4.4 (2.3–5.9) 5.3 (1.9–70.6)
Page 5 of 9Karlas et al. J Transl Med  (2017) 15:106 
concentrations. Those at risk for advanced fibrosis 
(>9.6 kPa) showed elevated levels of cf90 fragment con-
centrations and there are indications for a similar effect 
with cf222. Cf90 fragment concentrations were signifi-
cantly higher in NAFLD patients with increased AST 
values, while no such difference was observed for ALT 
values. Cf222 fragments were not significantly associ-
ated with either ALT or AST. Significant associations 
were seen between ferritin and both cfDNA fragments. 
Neither CAP nor 1H-MRS showed significant associa-
tions with concentration of cfDNA. Accordingly, no dif-
ferences in cfDNA concentrations between NAFLD 
patients with and without advanced steatosis were 
observed (Table 2).
To avoid collinearity, multivariate models considered 
only one measure of inflammatory activity and one of ste-
atosis (fat fraction, which is less related to liver stiffness 
than CAP). These corroborated the findings in Table  2, 
except that AST was no longer associated with cf90 upon 
taking liver stiffness and fat fraction into account (with 
sex as a covariate).
Based on these findings, we classified our NAFLD 
cohort according to disease severity:
(i)  NAFLD patients with normal liver enzymes and 
normal liver stiffness (“pure steatosis”),
(ii) patients with elevated liver enzymes (ALT and/or 
AST > ULN) and liver stiffness ≤7.0 kPa,
(iii) patients with elevated liver stiffness >7.0 kPa. All of 
them had elevated ALT and/or AST.
Plasma levels of both cfDNA fragments correlated with 
this classification (Fig. 2).
Thus, it is natural to question if cfDNA has clinical 
potential to help in identifying patients at risk for hepatic 
fibrosis, defined by elevated LSM. Areas under the curve 
from receiving operating characteristic were 0.78 (95% 
CI 0.63–0.93) for cf90 and 0.74 (95% CI 0.58–0.90) for 
cf222. The optimal cut-off for the former was 5.5 ng/mL 
(specificity 0.93, sensitivity 0.54) and 12.8 ng/mL (speci-
fity 0.77, sensitivity 0.69).
cfDNA integrity index
Using a linear mixed model with sex as a covariate and 
PCR batch as a random effect, the integrity index was not 
found to differ significantly between NAFLD patients and 
the control group (p =  0.52). In the NAFLD cohort, no 
Table 2 Association of cfDNA levels with features of disease severity in NAFLD patients
Values presented as median and range (ng/mL), p-values are taken from a linear mixed model with sex as a covariate and PCR-batch as a random term
1H-MRS single-proton magnetic resonance spectroscopy, CAP controlled attenuation parameter, rHLC relative hepatic lipid content, ALT alanine aminotransferase, AST 
aspartate aminotransferase, ULN upper limit of normal
Parameter cfDNA fragment Median (range) p value
Liver stiffness ≤7.0 kPa (n = 45) >7.0 kPa (n = 13)
90 bp 3.16 (1.29–7.31) 6.05 (2.41–23.13) <0.001
222 bp 11.32 (6.05–18.28) 14.41 (9.27–22.90) 0.0041
≤9.6 kPa (n = 48) >9.6 kPa (n = 10)
90 bp 3.22 (1.29–8.17) 5.78 (2.41–23.13) 0.011
222 bp 11.35 (6.05–19.74) 14.27 (9.27–22.90) 0.059
Inflammatory activity ALT ≤ ULN (n = 32) ALT > ULN (n = 26)
90 bp 3.08 (1.29–23.13) 3.93 (2.19–8.62) 0.26
222 bp 11.20 (6.92–22.90) 12.89 (6.05–19.74) 0.23
AST ≤ ULN (n = 40) AST > ULN (n = 18)
90 bp 3.05 (1.29–8.17) 5.18 (1.38–23.13) 0.038
222 bp 11.32 (6.05–19.74) 13.79 (8.66–22.90) 0.14
Ferritin ≤ ULN (n = 40) Ferritin > ULN (n = 17)
90 bp 3.21 (1.29–8.17) 4.70 (2.19–23.13) 0.026
222 bp 11.20 (6.05–19.74) 13.25 (10.0–22.90) 0.0071
Steatosis CAP ≤ 282 dB/m (n = 16) CAP > 282 dB/m (n = 42)
90 bp 3.51 (1.38–7.56) 3.71 (1.29–23.13) 0.12
222 bp 12.00 (6.05–18.28) 11.49 (6.91–22.90) 0.083
Fat fraction Fat fraction
(1H-MRS) ≤10% (n = 25) (1H-MRS) >10% (n = 33)
90 bp 2.97 (1.28–8.62) 3.90 (1.38–23.13) 0.13
222 bp 11.35 (6.92–18.28) 12.35 (6.05–22.90) 0.34
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association of the cfDNA integrity index with elevated 
aminotransferase levels, liver stiffness risk categories or 
advanced steatosis (defined in Table 2) could be observed 
(all p values >0.14).
Discussion
In light of increasing NAFLD prevalence, non-inva-
sive markers for the evaluation of disease severity are 
needed for decision making in clinical practice [6]. The 
progression of NAFLD is driven by inflammatory mecha-
nisms involving apoptosis and necrosis of hepatocytes, 
which ultimately result in the development of liver fibro-
sis and cirrhosis [22–25]. In the course of these inflam-
matory processes, DNA is released into the bloodstream. 
CfDNA has recently been reported as promising bio-
marker for risk and outcome prediction in a variety of 
diseases including cancer [10], organ damage [26] as well 
as acute graft rejection after solid organ transplantation 
[27–29].
We here demonstrate an association of circulating 
cfDNA fragments with established non-invasive markers 
of NAFLD severity, especially in patients with increased 
liver stiffness and elevated AST and ferritin levels, who 
are at high risk of ongoing NASH and of disease progres-
sion [5, 6, 30]. Elevation of serum aminotransferases, 
especially AST, and increased ferritin indicate oxidative 
stress and inflammatory activity in NAFLD [30–33]. The 
association of cf90 and cf222 with these markers prob-
ably reflects hepatic cfDNA release induced by inflamma-
tion and cell death, i.e. high NASH activity [4]. Moreover, 
further cellular systems involved in NASH pathogenesis, 
e.g. visceral fat, may contribute to the increase of cfDNA. 
Nishimoto and co-workers [34] recently linked adipose 
tissue inflammation to cfDNA released by adipocytes. 
Similar signaling mechanisms may play a role in NASH 
progression. A pro-inflammatory effect of cfDNA can 
be mediated through the secretion of TNF-α [35] and 
activation of Toll-like receptors [36, 37]. Future studies 
now need to clarify the origin of the cfDNA in patients 
with NASH and should also analyze its potential role 
as a modulator of inflammatory activity. Furthermore, 
longitudinal observations should address the kinetics of 
cfDNA release in the course of NAFLD, which might be 
associated with the ratio of long to short cfDNA frag-
ments [38]. The cfDNA integrity index, which was not 
associated with diseases severity in our cross-sectional 
analysis, may potentially provide additional information 
on dynamics of disease activity.
The analysis of cfDNA only requires a blood sample. 
Morover, short half-life makes this parameter interest-
ing for monitoring disease activity even in short term. 
CfDNA is already clinically relevant in prenatal testing 
[39], whereas its diagnostic role in the context of chronic 
liver diseases still needs to be defined. Sensitivity and 
specificity of cfDNA levels for detection of advanced 
NAFLD are limited in our cohort and biopsy-controlled 
large-scale studies are needed to assess its definite diag-
nostic accuracy. However, the combination of cfDNA 
with complementary non-invasive methods may pro-
vide higher accuracy for detection of NASH activity 
and significant fibrosis. In addition, circulating DNA 
markers may provide an alternative for patients with 
Fig. 2 Association of cell-free DNA with NAFLD severity. Serum levels 
of both (a) 90 bp (p = 0.001) and (b) 222 bp (p = 0.009) cfDNA frag-
ments correlate significantly with NAFLD severity (Kruskal–Wallis test 
and post hoc analysis, Asterisk indicates p values <0.05; double asterisk 
indicates p values <0.01). cfDNA cell-free DNA, NAFLD non-alcoholic 
fatty liver disease, ALT alanine aminotransferase, AST aspartate ami-
notransferase
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contraindications to TE and MRI, such as morbid obe-
sity [40]. Furthermore, circulating donor cfDNA has been 
suggested as a marker for graft injury in liver transplant 
recipients [29].
Future research directions should consider epige-
netic markers such as cfDNA methylation signatures to 
identify tissue-specific cell death [41]. Along these lines, 
recent diagnostic studies on cfDNA in patients with 
malignant diseases have studied tumor specific DNA 
fragments, which performed better than total plasma 
cfDNA [9]. In the liver setting, Hardy et al. have demon-
strated a higher methylation density on circulating DNA 
in NAFLD patients compared to controls, and methyla-
tion density was even higher in advanced than in mild 
fibrosis [42]. Therefore, the assessment of liver specific 
methylation may increase the diagnostic value of cfDNA 
measurement and should be incorporated in future study 
protocols.
This study has several limitations: Our findings rely on 
secondary analysis of data obtained for previous research. 
Therefore, the case number is limited and associations 
with further markers of oxidative stress and inflamma-
tion could not be studied. In addition, the non-invasive 
reference standards liver stiffness and CAP measurement 
as well as laboratory tests and 1H-MRS are only surro-
gates for NAFLD activity and severity with limited accu-
racy in individual cases, and cannot completely replace 
histological staging and grading [6]. However, we believe 
that due to the invasive nature of liver biopsy, which is 
usually restricted to patients with indeterminate diag-
nosis in clinical practise, a pilot study with non-inva-
sive surrogates is appropriate as a first approach. The 
methods used here, namely liver stiffness measurement 
with TE, have been approved as a biopsy alternative for 
fibrosis staging and correlate with prognosis in various 
chronic liver diseases [6]. However, we underline that our 
findings now require verification in prospective biopsy-
controlled studies, which should focus on inflammatory 
activity and hepatocyte apoptosis.
Conclusion
Cell-free plasma DNA plasma concentration correlates 
with established non-invasive markers of NAFLD activ-
ity and severity, and thus represents an interesting new 
biomarker for assessing NAFLD. Future studies should 
analyse the role of cfDNA as a mediator of tissue inflam-
mation, and should focus on its diagnostic value for 
discriminating patients at risk for NAFLD related mor-
bidity and mortality. Long-term follow-up is warranted 
to assess the correlation between cfDNA and disease 
progression.
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